Negative symptom improvement during cognitive rehabilitation: Results from a 2-year trial of Cognitive Enhancement Therapy

Psychiatry Research

Volumn 209, Issue 1, 2013, Pages 21-26

  Eack, Shaun M ^a,b   Mesholam Gately, Raquelle I ^c   Greenwald, Deborah P ^b   Hogarty, Susan S ^b   Keshavan, Matcheri S ^b,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cognitive rehabilitation; Negative symptoms; Neurocognition; Psychosocial treatment; Schizophrenia; Social cognition

Indexed keywords

ADULT; ARTICLE; COGNITIVE ENHANCEMENT THERAPY; COGNITIVE REHABILITATION; COGNITIVE THERAPY; CONTROLLED STUDY; DISEASE COURSE; EMOTION; FEMALE; HUMAN; INTELLIGENCE TEST; MAJOR CLINICAL STUDY; MALE; MOTOR RETARDATION; NEGATIVE SYNDROME; OUTPATIENT; PRIORITY JOURNAL; PSYCHOSOCIAL WITHDRAWAL; RANDOMIZED CONTROLLED TRIAL; SOCIAL COGNITION; TREATMENT RESPONSE;

COGNITIVE REHABILITATION; NEGATIVE SYMPTOMS; NEUROCOGNITION; PSYCHOSOCIAL TREATMENT; SCHIZOPHRENIA; SOCIAL COGNITION;

COGNITION DISORDERS; COGNITIVE THERAPY; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL BEHAVIOR; TREATMENT OUTCOME;

EID: 84881543290     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2013.03.020     Document Type: Article

References (57)

1. Ammons R.B., Ammons C.H. The Quick Test (QT): provisional manual. Psychological Reports 1962, 11(1):111-161.
2. Barch D.M., Dowd E.C. Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions. Schizophrenia Bulletin 2010, 36(5):919-934.
3. Bark N., Revheim N., Huq F., Khalderov V., Ganz Z.W., Medalia A. The impact of cognitive remediation on psychiatric symptoms of schizophrenia. Schizophrenia Research 2003, 63(3):229-235.
4. Bellucci D.M., Glaberman K., Haslam N. Computer-assisted cognitive rehabilitation reduces negative symptoms in the severely mentally ill. Schizophrenia Research 2003, 59(2-3):225-232.
5. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society. Series B (Methodological) 1995, 57(1):289-300.
6. Berridge K.C., Robinson T.E. Parsing reward. Trends in Neurosciences 2003, 26(9):507-513.
7. Buchanan R.W., Heinrichs D.W. The Neurological Evaluation Scale (NES): a structured instrument for the assessment of neurological signs in schizophrenia. Psychiatry Research 1989, 27(3):335-350.
8. Buchanan R.W., Javitt D.C., Marder S.R., Schooler N.R., Gold J.M., McMahon R.P., Heresco-Levy U., Carpenter W.T. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. American Journal of Psychiatry 2007, 164(10):1593-1602.
9. Buchanan R.W., Keefe R.S.E., Lieberman J.A., Barch D.M., Csernansky J.G., Goff D.C., Gold J.M., Green M.F., Jarskog L.F., Javitt D.C., Kimhy D., Kraus M.S., McEvoy J.P., Mesholam-Gately R.I., Seidman L.J., Ball M.P., McMahon R.P., Kern R.S., Robinson J., Marder S.R. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biological Psychiatry 2011, 69(5):442-449.
10. Couture S.M., Penn D.L., Roberts D.L. The functional significance of social cognition in schizophrenia: a review. Schizophrenia Bulletin 2006, 32(Suppl. 1):S44-63.
11. Culbertson, W.C., Zillmer, E.A., 1996. Tower of London-DX manual. Unpublished manuscript.
12. Delis D.C., Kramer J.H., Kaplan E., Ober B.A. California Verbal Learning Test Manual 1987, Psychological Corporation, San Antonio, TX.
13. Dempster A.P., Laird N.M., Rubin D.B. Maximum likelihood from incomplete data using the EM algorithm. Journal of the Royal Statistical Society. Series B (Methodological) 1977, 39(1):1-38.
14. Dowd E.C., Barch D.M. Pavlovian reward prediction and receipt in schizophrenia: relationship to anhedonia. PloS One 2012, 7(5):e35622.
15. Eack S.M., Greeno C.G., Pogue-Geile M.F., Newhill C.E., Hogarty G.E., Keshavan M.S. Assessing social-cognitive deficits in schizophrenia with the Mayer-Salovey-Caruso Emotional Intelligence Test. Schizophrenia Bulletin 2010, 36(2):370-380.
16. Eack S.M., Greenwald D.P., Hogarty S.S., Keshavan M.S. One-year durability of the effects of Cognitive Enhancement Therapy on functional outcome in early schizophrenia. Schizophrenia Research 2010, 120(1):210-216.
17. Eack S.M., Greenwald D.P., Hogarty S.S., Cooley S.J., DiBarry A.L., Montrose D.M., Keshavan M.S. Cognitive Enhancement Therapy for early-course schizophrenia: effects of a two-year randomized controlled trial. Psychiatric Services 2009, 60(11):1468-1476.
18. Eack S.M., Hogarty G.E., Cho R.Y., Prasad K.M.R., Greenwald D.P., Hogarty S.S., Keshavan M.S. Neuroprotective effects of Cognitive Enhancement Therapy against gray matter loss in early schizophrenia: results from a two-year randomized controlled trial. Archives of General Psychiatry 2010, 67(7):674-682.
19. Eack S.M., Hogarty G.E., Greenwald D.P., Hogarty S.S., Keshavan M.S. Effects of Cognitive Enhancement Therapy on employment outcomes in early schizophrenia: results from a two-year randomized trial. Research on Social Work Practice 2011, 21(3):32-42.
20. Erhart S.M., Marder S.R., Carpenter W.T. Treatment of schizophrenia negative symptoms: future prospects. Schizophrenia Bulletin 2006, 32(2):234-237.
21. First, M.B., Spitzer, R.L., Gibbon, M., Williams, J.B.W., 2002. Structured Clinical Interview For DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. Biometrics Research, New York State Psychiatric Institute, New York, NY.
22. Gold J.M., Waltz J.A., Matveeva T.M., Kasanova Z., Strauss G.P., Herbener E.S., Collins A.G.E., Frank M.J. Negative symptoms and the failure to represent the expected reward value of actions: behavioral and computational modeling evidence. Archives of General Psychiatry 2012, 69(2):129-138.
23. Green M.F., Kern R.S., Braff D.L., Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the right stuff?. Schizophrenia Bulletin 2000, 26(1):119-136.
24. Green M.F., Nuechterlein K.H., Gold J.M., Barch D.M., Cohen J., Essock S., Fenton W.S., Frese F., Goldberg T.E., Heaton R.K., Keefe R.S.E., Kern R.S., Kraemer H.C., Stover E., Weinberger D.R., Zalcman S., Marder S.R. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biological Psychiatry 2004, 56(5):301-307.
25. Harvey P.D., Koren D., Reichenberg A., Bowie C.R. Negative symptoms and cognitive deficits: what is the nature of their relationship. Schizophrenia Bulletin 2006, 32(2):250-258.
26. Heaton R.K., Chelune G.J., Talley J.L., Kay G.G., Curtiss G. Wisconsin Card Sorting Test Manual: Revised and Expanded 1993, Psychological Assessment Resources Inc, Odessa, FL.
27. Heinrichs R.W., Zakzanis K.K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998, 12(3):426-445.
28. Hogarty G.E. Personal Therapy for Schizophrenia and Related Disorders: A Guide to Individualized Treatment 2002, Guilford, New York.
29. Hogarty, G.E., Greenwald, D.P., 2006. Cognitive Enhancement Therapy: The Training Manual. University of Pittsburgh Medical Center: Authors. Available through. http://www.CognitiveEnhancementTherapy.com.
30. Hogarty G.E., Flesher S., Ulrich R., Carter M., Greenwald D., Pogue-Geile M., Keshavan M., Cooley S., DiBarry A.L., Garrett A., Parepally H., Zoretich R. Cognitive enhancement therapy for schizophrenia. Effects of a 2-year randomized trial on cognition and behavior. Archives of General Psychiatry 2004, 61(9):866-876.
31. Hogarty G.E., Greenwald D.P., Eack S.M. Durability and mechanism of effects of Cognitive Enhancement Therapy. Psychiatric Services 2006, 57(12):1751-1757.
32. Hogarty G.E., Greenwald D., Ulrich R.F., Kornblith S.J., Dibarry A.L., Cooley S., Carter M., Flesher S. Three-year trials of personal therapy among schizophrenic patients living with or independent of family: II. Effects on adjustment of patients. American Journal of Psychiatry 1997, 154(11):1514-1524.
33. Karlsson R.M., Tanaka K., Saksida L.M., Bussey T.J., Heilig M., Holmes A. Assessment of glutamate transporter GLAST (EAAT1)-deficient mice for phenotypes relevant to the negative and executive/cognitive symptoms of schizophrenia. Neuropsychopharmacology 2008, 34(6):1578-1589.
34. Keefe R.S.E., Buchanan R.W., Marder S.R., Schooler N.R., Dugar A., Zivkov M., Stewart M. Clinical Trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far. Schizophrenia Bulletin 2013, 39(2):417-435.
35. Kirkpatrick B., Fenton W.S., Carpenter W.T., Marder S.R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophrenia Bulletin 2006, 32(2):214-219.
36. Labrie V., Lipina T., Roder J.C. Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia. Psychopharmacology 2008, 200(2):217-230.
37. Marx C.E., Keefe R.S.E., Buchanan R.W., Hamer R.M., Kilts J.D., Bradford D.W., Strauss J.L., Naylor J.C., Payne V.M., Lieberman J.A., Savitz A.J., Leimone L.A., Dunn L., Porcu P., Morrow A.L., Shampine L.J. Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology 2009, 34(8):1885-1903.
38. Mayer J.D., Salovey P., Caruso D.R., Sitarenios G. Measuring emotional intelligence with the MSCEIT V2.0. Emotion 2003, 3(1):97-105.
39. McEvoy J.P., Hogarty G.E., Steingard S. Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Archives of General Psychiatry 1991, 48(8):739-745.
40. McGurk S.R., Twamley E.W., Sitzer D.I., McHugo G.J., Mueser K.T. A meta-analysis of cognitive remediation in schizophrenia. American Journal of Psychiatry 2007, 164(12):1791-1802.
41. Mesholam-Gately R.I., Giuliano A.J., Goff K.P., Faraone S.V., Seidman L.J. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 2009, 23(3):315-336.
42. Nuechterlein K.H., Green M.F., Kern R.S., Baade L.E., Barch D.M., Cohen J.D., Essock S., Fenton W.S., Frese I.I.I, F.J., Gold J.M., Goldberg T., Heaton R.K., Keefe R.S.E., Kraemer H., Meshalom-Gately R.I., Seidman L.J., Stover E., Weinberger D.R., Young A.S., Zalcman S., Marder S.R. The MATRICS consensus cognitive battery, Part 1: test selection, reliability, and validity. American Journal of Psychiatry 2008, 165(2):203-213.
43. Overall J.E., Gorham D.R. The Brief Psychiatric Rating Scale. Psychological Reports 1962, 10:799-812.
44. Penn D.L., Corrigan P.W., Bentall R.P., Racenstein J., Newman L. Social cognition in schizophrenia. Psychological Bulletin 1997, 121(1):114-132.
45. Reitan R.M., Waltson D. The Halstead-Reitan Neuropsychological Test Battery 1985, Neuropsychology Press, Tucson, AZ.
46. Salovey P., Mayer J.D. Emotional intelligence. Imagination, Cognition, and Personality 1990, 9(3):185-221.
47. Schafer J.L., Graham J.W. Missing data: our view of the state of the art. Psychological Methods 2002, 7(2):147-177.
48. Schultz W. Multiple reward signals in the brain. Nature Reviews Neuroscience 2000, 1(3):199-208.
49. Shafer A. Meta-analysis of the Brief Psychiatric Rating Scale factor structure. Psychological Assessment 2005, 17(3):324-335.
50. Strauss G.P., Frank M.J., Waltz J.A., Kasanova Z., Herbener E.S., Gold J.M. Deficits in positive reinforcement learning and uncertainty-driven exploration are associated with distinct aspects of negative symptoms in schizophrenia. Biological Psychiatry 2011, 69(5):424-431.
51. Subramaniam K., Luks T.L., Fisher M., Simpson G.V., Nagarajan S., Vinogradov S. Computerized cognitive training restores neural activity within the reality monitoring network in schizophrenia. Neuron 2012, 73(4):842-853.
52. Wechsler D. Manual for the Wechsler Memory Scale-Revised 1987, Psychological Corp, San Antonio, TX.
53. Wechsler D. Wechsler Adult Intelligence Scale-Revised 1981, Psychological Corp, New York.
54. Wing J.K. A simple and reliable subclassification of chronic schizophrenia. Journal Mental Science 1961, 107:862-875.
55. Wise R.A. Brain reward circuitry: insights from unsensed incentives. Neuron 2002, 36(2):229-240.
56. Wykes T., Huddy V., Cellard C., McGurk S.R., Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. American Journal of Psychiatry 2011, 168(5):472-485.
57. Ziauddeen H., Murray G.K. The relevance of reward pathways for schizophrenia. Current Opinion in Psychiatry 2010, 23(2):91-96.